Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kirsten Bell-Burdett"'
Autor:
Alfredo Falcone, Chiara Cremolini, Jing Lyu, Dominic T. Moore, Daniele Rossini, Richard M. Goldberg, Anastasia Ivanova, Yingmiao Liu, Ace J. Hatch, Alexander B. Sibley, Kelli Hammond, Andrew B. Nixon, Federica Marmorino, Federico Innocenti, Hanna K. Sanoff, Mark D. Starr, Kouros Owzar, John C. Brady, Kirsten Bell Burdett, Michael S. Lee
Publikováno v:
Molecular Cancer Therapeutics. 19:2146-2154
Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, met
Autor:
Al B. Benson, Kristen Carroll, Ryan Jones, Deva Mahalingam, Kirsten Bell Burdett, Guang Yu Yang, Michael C. Burns, Masha Kocherginsky
Publikováno v:
Journal of Clinical Oncology. 38:242-242
242 Background: While the 5-year recurrence rate in early stage CRC is low (12%) and there is currently limited role of adjuvant chemotherapy in such cases, a unique subset of patients (pts) will have late recurrences. To identify molecular signature
Autor:
Masha Kocherginsky, Michael C. Burns, Kirsten Bell Burdett, Guang Yu Yang, Kristen Carroll, Ryan Jones, Al B. Benson, Devalingam Mahalingam
Publikováno v:
Journal of Clinical Oncology. 38:237-237
237 Background: NGS analysis has identified molecular alterations that have predictive and prognostic implications in advanced RC. However, its role in identifying predictive signatures of chemoradiotherapy response in RC remains largely unexplored.
Autor:
Dominic T. Moore, Andrew B. Nixon, Yingmiao Liu, J. Chris Brady, Bert H. O'Neil, Kirsten Bell Burdett, Kelli Hammond, Hanna K. Sanoff, Mark D. Starr, Federico Innocenti, Ace J. Hatch, Anastasia Ivanova, Michael Sangmin Lee, Kouros Owzar
Publikováno v:
Journal of Clinical Oncology. 37:587-587
587 Background: The LCCC1029 trial demonstrated that addition of the multitargeted kinase inhibitor regorafenib (Rego) to FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts) modestly prolonged progression-free survival (PFS). In this prepla